Evestra, Inc. is an emerging biopharmaceutical research and development company with a focus on female healthcare product development. The company was established as a Delaware corporation in October 2007 as a spin-off of the Organic Chemistry Department of Texas Biomedical Research Institute (formerly Southwest Foundation for Biomedical Research (SFBR)), located in San Antonio, Texas. Evestra, Inc. began actual operations in April of 2008. Evestra’s facilities are located on the Tx Biomed campus and include a GMP manufacturing site. Evestra is conducting research and product development in a number of in-demand, but as yet unmet, medical needs areas of women’s health such as endometriosis and hormonal-dependent breast cancer. The company is also pursuing new compounds for HRT and has established a strong intellectual property position. Evestra holds a long-standing contract with the National Institute of Child Health Development and is collaborating with the NIH in synthesizing, for subsequent biological testing, a variety of steroid compounds targeting fertility control and HRT. Through this collaboration, which includes leading endocrinologists in the University of Texas Health Science system, the biochemical research team that now is an integral part of Evestra’s family made key contributions to the development of the first contraceptive (“the pill”), introduced to mainstream healthcare in the 1960s. Evestra applies its founders’ experience in RD of steroid-based drugs, combined with a proven track record in commercializing female healthcare products, to provide a solid foundation for the company in its goal to design and produce differentiated new chemical entities.